<p>AngioDynamics（納斯達克：ANGO - 獲取免費報告）預計將在 2026 年 1 月 6 日星期二市場開盤前發佈其 2026 財年第二季度業績。分析師預計 AngioDynamics 每股收益為（$0.10），季度收入為 7643.30 萬美元。AngioDynamics 已將其 2026 財年的指導目標設定為每股收益-0.330 至-0.230。個人可以訪問公司即將發佈的 2026 財年第二季度業績頁面，以獲取有關定於 2026 年 1 月 6 日東部時間上午 8:00 的電話會議的最新信息。</p>
<p>獲取 <strong>AngioDynamics</strong> 警報：</p>
<p>AngioDynamics（納斯達克：ANGO - 獲取免費報告）最近在 2023 年 10 月 2 日星期四發佈了其財報。這家醫療器械供應商報告的季度每股收益為（$0.10），超出分析師共識預期的（$0.12）$0.02。該公司在本季度的收入為 7571 萬美元，而分析師預期為 7269 萬美元。AngioDynamics 的股本回報率為-3.16%，淨利潤率為-10.67%。與去年同期相比，AngioDynamics 的收入增長了 12.1%。在去年同期，該公司每股收益為（$0.11）。分析師平均預計 AngioDynamics 在當前財年和下一個財年每股收益均為$0。</p>
<h2>AngioDynamics 價格表現</h2>
<p>ANGO 股票在星期二開盤價為$12.87。該公司的 50 日移動平均線為$12.61，200 日移動平均線為$10.91。該公司的市值為 5.3024 億美元，市盈率為-16.50，貝塔值為 0.49。AngioDynamics 的 1 年最低價為$8.27，1 年最高價為$13.99。</p>
<h2>內部交易活動</h2>
<p>在其他新聞中，首席執行官 James C. Clemmer 在 2023 年 10 月 9 日星期四購買了 10,000 股公司的股票，交易價格為每股$11.15，總價值為$111,500.00。交易完成後，首席執行官直接持有 882,529 股公司股票，價值約為$9,840,198.35。這代表其持股比例增加了 1.15%。該購買在向證券交易委員會的備案中披露，相關信息可通過此鏈接訪問。此外，高級副總裁 Lawrence T. Weiss 在 2023 年 10 月 21 日星期二購買了 10,000 股股票，交易價格為每股$11.81，總交易額為$118,100.00。交易完成後，該高級副總裁持有 93,597 股公司股票，價值約為$1,105,380.57。該交易使其持股比例增加了 11.96%。有關此購買的更多詳細信息可在官方 SEC 披露中找到。在過去的九十天裏，內部人士購買了價值$239,532 的 20,890 股公司股票。公司內部人士持有 6.00% 的公司股票。</p>
<h2>機構投資者對 AngioDynamics 的看法</h2>
<p>一些機構投資者和對沖基金最近對 ANGO 的持倉進行了調整。懷俄明州購買了 AngioDynamics 的新股份，價值約為$31,000。拉塞爾投資集團在第三季度將其在 AngioDynamics 的持倉增加了 329.5%。拉塞爾投資集團現在擁有 4,188 股醫療器械供應商的股票，價值$47,000，此前在上個季度又購買了 3,213 股。塔樓研究資本公司在第二季度將其在 AngioDynamics 的持倉增加了 359.0%。塔樓研究資本公司現在擁有 5,457 股醫療器械供應商的股票，價值$54,000，此前在此期間又購買了 4,268 股。法國巴黎銀行金融市場在第三季度將其在 AngioDynamics 的持倉增加了 106.0%。法國巴黎銀行金融市場現在擁有 7,473 股醫療器械供應商的股票，價值$83,000，此前在上個季度又購買了 3,846 股。最後，雷蒙德·詹姆斯金融公司在第二季度購買了 AngioDynamics 的新股份，價值約為$90,000。89.43% 的股票由對沖基金和其他機構投資者持有。</p>
<h2>分析師評級調整</h2>
<p>一些股票研究分析師對該股票發表了評論。Weiss Ratings 在 2023 年 10 月 8 日的研究報告中重新發布了對 AngioDynamics 股票的 “賣出（d-）” 評級。Canaccord Genuity Group 在 2023 年 10 月 3 日的報告中將 AngioDynamics 的目標價格從$17.00 提高到$18.00，並給予該公司 “買入” 評級。最後，華爾街 Zen 在 2023 年 12 月 21 日的研究報告中將 AngioDynamics 的評級從 “買入” 下調至 “持有”。三位研究分析師對該股票給予了買入評級，一位分析師給予了賣出評級。根據 MarketBeat.com 的數據，該股票目前的共識評級為 “適度買入”，共識目標價格為$19.33。</p>
<p><strong>查看我們對 AngioDynamics 的最新分析</strong></p>
<h2>AngioDynamics 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>AngioDynamics, Inc 是一家總部位於紐約拉瑟姆的醫療技術公司，開發、製造和銷售一系列微創醫療設備。公司的產品專注於三個核心領域：血管通路、外周血管介入和介入腫瘤學。其解決方案旨在改善手術結果，減少併發症，並提高醫院和門診環境中的患者舒適度。</p>
<p>在血管通路領域，AngioDynamics 提供一系列設備，包括植入式端口、外周插入中心導管（PICCs）、血液透析導管和特殊血液管理產品。</p>
<h2>特色文章</h2>
<ul>
<li>我們更看好的五隻股票超過 AngioDynamics</li>
<li>華爾街股票挑選者評選 2026 年第一隻股票</li>
<li>請勿刪除，立即閲讀</li>
<li>在美國鬼城發現的$100 萬億 “人工智能金屬”</li>
<li>現在拋售這五隻股票！</li>
<li>特朗普的新人工智能預算剛剛通過——一隻股票可能飆升</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU5HTw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU5HTw"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1,000 美元在 AngioDynamics 嗎？</h2>
<p>在考慮 AngioDynamics 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 AngioDynamics 並不在名單上。</p>
<p>雖然 AngioDynamics 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

阿吉奧動態

<p>AngioDynamics（納斯達克代碼：ANGO）將於 1 月 6 日發佈 2026 財年第二季度財報，分析師預計每股虧損 0.10 美元，收入為 7643 萬美元。該公司已提供 2026 財年的指導，預計每股收益在-0.330 到-0.230 之間。最近的內部交易包括首席執行官 James C. Clemmer 購買了 10,000 股。機構投資者也增加了對 AngioDynamics 的持股，89.43% 的股票由對沖基金持有。分析師的評級各異，普遍共識為 “適度買入”</p>

<p>AngioDynamics (NASDAQ:ANGO - Get Free Report) is expected to be posting its Q2 2026 results before the market opens on Tuesday, January 6th. Analysts expect AngioDynamics to post earnings of ($0.10) per share and revenue of $76.4330 million for the quarter. AngioDynamics has set its FY 2026 guidance at -0.330--0.230 EPS. Individuals may visit the the company's upcoming Q2 2026 earning results page for the latest details on the call scheduled for Tuesday, January 6, 2026 at 8:00 AM ET.</p>
<div class="lb-trans"><p>AngioDynamics（納斯達克：ANGO - 獲取免費報告）預計將在 2026 年 1 月 6 日星期二市場開盤前發佈其 2026 財年第二季度業績。分析師預計 AngioDynamics 每股收益為（$0.10），季度收入為 7643.30 萬美元。AngioDynamics 已將其 2026 財年的指導目標設定為每股收益-0.330 至-0.230。個人可以訪問公司即將發佈的 2026 財年第二季度業績頁面，以獲取有關定於 2026 年 1 月 6 日東部時間上午 8:00 的電話會議的最新信息。</p>
</div><p>Get <strong>AngioDynamics</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>AngioDynamics</strong> 警報：</p>
</div><p>AngioDynamics (NASDAQ:ANGO - Get Free Report) last released its earnings results on Thursday, October 2nd. The medical instruments supplier reported ($0.10) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.12) by $0.02. The firm had revenue of $75.71 million during the quarter, compared to analyst estimates of $72.69 million. AngioDynamics had a negative return on equity of 3.16% and a negative net margin of 10.67%.AngioDynamics's revenue was up 12.1% compared to the same quarter last year. During the same period last year, the business posted ($0.11) earnings per share. On average, analysts expect AngioDynamics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.</p>
<div class="lb-trans"><p>AngioDynamics（納斯達克：ANGO - 獲取免費報告）最近在 2023 年 10 月 2 日星期四發佈了其財報。這家醫療器械供應商報告的季度每股收益為（$0.10），超出分析師共識預期的（$0.12）$0.02。該公司在本季度的收入為 7571 萬美元，而分析師預期為 7269 萬美元。AngioDynamics 的股本回報率為-3.16%，淨利潤率為-10.67%。與去年同期相比，AngioDynamics 的收入增長了 12.1%。在去年同期，該公司每股收益為（$0.11）。分析師平均預計 AngioDynamics 在當前財年和下一個財年每股收益均為$0。</p>
</div><h2>AngioDynamics Price Performance</h2>
<div class="lb-trans"><h2>AngioDynamics 價格表現</h2>
</div><p>ANGO stock opened at $12.87 on Tuesday. The business's 50-day moving average is $12.61 and its two-hundred day moving average is $10.91. The firm has a market capitalization of $530.24 million, a P/E ratio of -16.50 and a beta of 0.49. AngioDynamics has a 1 year low of $8.27 and a 1 year high of $13.99.</p>
<div class="lb-trans"><p>ANGO 股票在星期二開盤價為$12.87。該公司的 50 日移動平均線為$12.61，200 日移動平均線為$10.91。該公司的市值為 5.3024 億美元，市盈率為-16.50，貝塔值為 0.49。AngioDynamics 的 1 年最低價為$8.27，1 年最高價為$13.99。</p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>內部交易活動</h2>
</div><p>In other news, CEO James C. Clemmer purchased 10,000 shares of the business's stock in a transaction on Thursday, October 9th. The shares were bought at an average price of $11.15 per share, with a total value of $111,500.00. Following the completion of the transaction, the chief executive officer directly owned 882,529 shares in the company, valued at approximately $9,840,198.35. This represents a 1.15% increase in their position. The purchase was disclosed in a filing with the Securities &amp; Exchange Commission, which is accessible through this hyperlink. Also, SVP Lawrence T. Weiss bought 10,000 shares of the stock in a transaction dated Tuesday, October 21st. The shares were acquired at an average price of $11.81 per share, for a total transaction of $118,100.00. Following the completion of the transaction, the senior vice president owned 93,597 shares of the company's stock, valued at approximately $1,105,380.57. The trade was a 11.96% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last ninety days, insiders have acquired 20,890 shares of company stock worth $239,532. Corporate insiders own 6.00% of the company's stock.</p>
<div class="lb-trans"><p>在其他新聞中，首席執行官 James C. Clemmer 在 2023 年 10 月 9 日星期四購買了 10,000 股公司的股票，交易價格為每股$11.15，總價值為$111,500.00。交易完成後，首席執行官直接持有 882,529 股公司股票，價值約為$9,840,198.35。這代表其持股比例增加了 1.15%。該購買在向證券交易委員會的備案中披露，相關信息可通過此鏈接訪問。此外，高級副總裁 Lawrence T. Weiss 在 2023 年 10 月 21 日星期二購買了 10,000 股股票，交易價格為每股$11.81，總交易額為$118,100.00。交易完成後，該高級副總裁持有 93,597 股公司股票，價值約為$1,105,380.57。該交易使其持股比例增加了 11.96%。有關此購買的更多詳細信息可在官方 SEC 披露中找到。在過去的九十天裏，內部人士購買了價值$239,532 的 20,890 股公司股票。公司內部人士持有 6.00% 的公司股票。</p>
</div><h2>Institutional Investors Weigh In On AngioDynamics</h2>
<div class="lb-trans"><h2>機構投資者對 AngioDynamics 的看法</h2>
</div><p>A number of institutional investors and hedge funds have recently made changes to their positions in ANGO. State of Wyoming purchased a new stake in shares of AngioDynamics in the second quarter valued at approximately $31,000. Russell Investments Group Ltd. boosted its position in shares of AngioDynamics by 329.5% during the 3rd quarter. Russell Investments Group Ltd. now owns 4,188 shares of the medical instruments supplier's stock worth $47,000 after purchasing an additional 3,213 shares in the last quarter. Tower Research Capital LLC TRC grew its stake in shares of AngioDynamics by 359.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,457 shares of the medical instruments supplier's stock worth $54,000 after purchasing an additional 4,268 shares during the period. BNP Paribas Financial Markets increased its holdings in shares of AngioDynamics by 106.0% in the 3rd quarter. BNP Paribas Financial Markets now owns 7,473 shares of the medical instruments supplier's stock valued at $83,000 after purchasing an additional 3,846 shares in the last quarter. Finally, Raymond James Financial Inc. purchased a new position in shares of AngioDynamics in the 2nd quarter valued at about $90,000. 89.43% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>一些機構投資者和對沖基金最近對 ANGO 的持倉進行了調整。懷俄明州購買了 AngioDynamics 的新股份，價值約為$31,000。拉塞爾投資集團在第三季度將其在 AngioDynamics 的持倉增加了 329.5%。拉塞爾投資集團現在擁有 4,188 股醫療器械供應商的股票，價值$47,000，此前在上個季度又購買了 3,213 股。塔樓研究資本公司在第二季度將其在 AngioDynamics 的持倉增加了 359.0%。塔樓研究資本公司現在擁有 5,457 股醫療器械供應商的股票，價值$54,000，此前在此期間又購買了 4,268 股。法國巴黎銀行金融市場在第三季度將其在 AngioDynamics 的持倉增加了 106.0%。法國巴黎銀行金融市場現在擁有 7,473 股醫療器械供應商的股票，價值$83,000，此前在上個季度又購買了 3,846 股。最後，雷蒙德·詹姆斯金融公司在第二季度購買了 AngioDynamics 的新股份，價值約為$90,000。89.43% 的股票由對沖基金和其他機構投資者持有。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析師評級調整</h2>
</div><p>A number of equities research analysts have commented on the stock. Weiss Ratings reissued a &#34;sell (d-)&#34; rating on shares of AngioDynamics in a research report on Wednesday, October 8th. Canaccord Genuity Group increased their target price on AngioDynamics from $17.00 to $18.00 and gave the company a &#34;buy&#34; rating in a report on Friday, October 3rd. Finally, Wall Street Zen cut AngioDynamics from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a research note on Sunday, December 21st. Three research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $19.33.</p>
<div class="lb-trans"><p>一些股票研究分析師對該股票發表了評論。Weiss Ratings 在 2023 年 10 月 8 日的研究報告中重新發布了對 AngioDynamics 股票的 “賣出（d-）” 評級。Canaccord Genuity Group 在 2023 年 10 月 3 日的報告中將 AngioDynamics 的目標價格從$17.00 提高到$18.00，並給予該公司 “買入” 評級。最後，華爾街 Zen 在 2023 年 12 月 21 日的研究報告中將 AngioDynamics 的評級從 “買入” 下調至 “持有”。三位研究分析師對該股票給予了買入評級，一位分析師給予了賣出評級。根據 MarketBeat.com 的數據，該股票目前的共識評級為 “適度買入”，共識目標價格為$19.33。</p>
</div><p><strong>Check Out Our Latest Analysis on AngioDynamics</strong></p>
<div class="lb-trans"><p><strong>查看我們對 AngioDynamics 的最新分析</strong></p>
</div><h2>AngioDynamics Company Profile</h2>
<div class="lb-trans"><h2>AngioDynamics 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company's products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.</p>
<div class="lb-trans"><p>AngioDynamics, Inc 是一家總部位於紐約拉瑟姆的醫療技術公司，開發、製造和銷售一系列微創醫療設備。公司的產品專注於三個核心領域：血管通路、外周血管介入和介入腫瘤學。其解決方案旨在改善手術結果，減少併發症，並提高醫院和門診環境中的患者舒適度。</p>
</div><p>In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.</p>
<div class="lb-trans"><p>在血管通路領域，AngioDynamics 提供一系列設備，包括植入式端口、外周插入中心導管（PICCs）、血液透析導管和特殊血液管理產品。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>特色文章</h2>
</div><ul>
<li>Five stocks we like better than AngioDynamics</li>
<li>Wall Street Stockpicker Names #1 Stock of 2026</li>
<li>Do not delete, read immediately</li>
<li>$100 Trillion “AI Metal” Found in American Ghost Town</li>
<li>Drop these 5 stocks now!</li>
<li>Trump’s new AI budget just passed — one stock could soar</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票超過 AngioDynamics</li>
<li>華爾街股票挑選者評選 2026 年第一隻股票</li>
<li>請勿刪除，立即閲讀</li>
<li>在美國鬼城發現的$100 萬億 “人工智能金屬”</li>
<li>現在拋售這五隻股票！</li>
<li>特朗普的新人工智能預算剛剛通過——一隻股票可能飆升</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU5HTw" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=ANGO"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in AngioDynamics Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 AngioDynamics 嗎？</h2>
</div><p>Before you consider AngioDynamics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 AngioDynamics 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AngioDynamics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 AngioDynamics 並不在名單上。</p>
</div><p>While AngioDynamics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 AngioDynamics 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Angiodynamics（ANGO）將於週二公佈財報